This biotech dealmaker — tied to Merck, Travere — is in a profit-taking zone
Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.
Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.